Mark Gustafson

Mark Gustafson, listed as board member, appears in our data through filings on Alzamend Neuro, Inc. shares, published by SEC (Form 4). We count 5 filings; the first trade dates from 13 September 2021 and the latest from 31 March 2022.

The open-market record consists of 2 sales worth €72k, with no purchase. Outside the open market, there are 3 option exercises. Since January 2022: no purchases and 1 sale on the market.

Most recently, on 4 April 2022, the filings show an open-market sale worth €22k in Alzamend Neuro, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.